Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamapediatrics.2020.0635 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Journal of Experimental Psychology: Human Perception and Performance 2000-2005.
J Exp Psychol Hum Percept Perform
January 2025
Department of Psychology, University of California, Riverside.
The present author was honored to serve as editor of Journal of Experimental Psychology: Human Perception and Performance (JEP:HPP) for the 2000-2005 volumes, carrying on the work of his predecessors. Along with the happiness and pride he felt during his time as editor, he also experienced disquiet. He captures the source of the unease with an anecdote from when he was an independent researcher.
View Article and Find Full Text PDFCorrection: Kidney lesions and risk of cardiovascular events in biopsy-proven diabetic kidney disease with type 2 diabetes.
Clin Exp Nephrol
January 2025
Department of Nephrology and Rheumatology, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.
A randomized prospective study to compare the efficacy of 308-nm light-emitting diode and 308-nm excimer lamp in the treatment of facial vitiligo.
Arch Dermatol Res
January 2025
Department of Physiotherapy, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, 210042, China.
Background: Previous studies have proven that 308-nm light-emitting diode(308-nm LED)and 308-nm excimer lamp(308-nm MEL) are effective in treating vitiligo, but there is a lack of comparison of their efficacy for facial lesions.
Objective: To evaluate and contrast the treatment success rates of 308-nm LED versus 308-nm excimer lamp in managing facial lesions among patients suffering from stable non-segmental vitiligo.
Methods: The enrolled 119 patients with 145 lesions were randomly assigned to receive 308-nm LED or 308-nm MEL for two months.
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.
Curr Oncol Rep
January 2025
Susan F. Smith Center for Women's Cancers, Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
Purpose Of Review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.
Recent Findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures.
Background: Plasma biomarkers have been increasingly studied in Alzheimer's disease due to their potentially high accessibility, affordability, and low invasiveness. Recent studies have shown that baseline plasma levels are capable of predicting cognitive decline in cognitively unimpaired subjects (CU) and with mild cognitive impairment (MCI). Despite the fact that neuroimaging biomarkers are also strong predictors, it is still unclear how well they perform when compared to plasma biomarkers in predicting cognitive deterioration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!